GlassScriptPhysician profile
Ricardo A Silva
NPI 1619979788
$32,254.10
in general payments reported to CMS, 2019-2025
49 companies · $4,506 in 2025
The $4,506 reported for 2025 was more than what 87% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $2,531 · 2021: $2,751 · 2022: $3,841 · 2023: $4,205 · 2024: $3,643 · 2025: $4,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,354.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $7,006.72 | 2019-2025 | |
| Abbvie INC. | $4,368.92 | 2019-2025 | Synthroid |
| Abbott Laboratories | $3,495.79 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $2,827.57 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Insulet Corporation | $1,600.25 | 2019-2025 | Omnipod |
| Mannkind Corporation | $1,317.87 | 2019-2024 | Afrezza |
| Lilly USA, LLC | $1,181.78 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Corcept Therapeutics | $1,130.46 | 2020-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $978.19 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $945.65 | 2019-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $817.03 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Medtronic, INC. | $710.28 | 2021-2025 | Minimed 780g, Inceptiv |
| Amgen INC. | $637.81 | 2019-2025 | Tepezza, Evenity, Repatha |
| Radius Health, INC. | $594.85 | 2019-2025 | |
| Horizon Therapeutics Plc | $512.01 | 2019-2023 | Tepezza |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $471.09 | 2019-2023 | Farxiga |
| Dexcom, INC. | $470.22 | 2020-2025 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $346.31 | 2022-2025 | Strensiq |
| Tandem Diabetes Care, INC. | $325.68 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ibsa Pharma INC. | $264.74 | 2019-2025 | Tirosint, Licart, Flector |
| Ascendis Pharma Endocrinology INC | $239.90 | 2023-2025 | Yorvipath |
| Cequr Corporation | $226.54 | 2025 | Cequr Simplicity |
| Sequel Med Tech, LLC | $210.05 | 2025 | Twiist |
| Valeritas, INC. | $201.86 | 2019 | |
| Amneal Pharmaceuticals LLC | $174.20 | 2020-2024 | Unithroid |
| Merck Sharp & Dohme LLC | $158.16 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $119.29 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $108.73 | 2021-2023 | |
| Zealand Pharma US, INC. | $106.26 | 2021 | |
| Janssen Pharmaceuticals, INC | $86.34 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $77.74 | 2025 | |
| Shire North American Group INC | $67.51 | 2019 | |
| Boston Scientific Corporation | $61.83 | 2024-2025 | General - Pain Management |
| Rhythm Pharmaceuticals, INC. | $57.30 | 2025 | Imcivree |
| Astellas Pharma US INC | $52.12 | 2023 | Veozah, Myrbetriq |
| Medtronic Minimed, INC. | $49.34 | 2019 | |
| Lifescan, INC. | $45.14 | 2020-2021 | |
| Globus Medical, INC. | $36.06 | 2025 | Senza |
| Senseonics, Incorporated | $35.00 | 2019-2020 | |
| Chiesi USA, INC. | $34.88 | 2025 | Mycapssa |
| Philips North America LLC | $30.10 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $24.42 | 2022 | |
| Acella Pharmaceuticals, LLC | $16.47 | 2025 | NP Thyroid 60 |
| Recordati_rare_diseases_inc. | $16.02 | 2023 | Isturisa |
| Almatica Pharma LLC | $15.62 | 2024 | Teriparatide |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ricardo Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.